- No, there's no evidence that GLP-1 patches cause weight loss. As of September 2026, no human trial has tested one. The patches contain no GLP-1 medicine, such as semaglutide or tirzepatide [35][23].
- Skin blocks large molecules, so a skin patch can't deliver GLP-1 drugs. Semaglutide weighs 4,113.58 daltons and tirzepatide 4,813.53. That is about 8 to 10 times the 500-dalton limit for skin [2][25][8].
- Patch ingredients such as berberine and cinnamon show small or no weight effects even when swallowed. No study shows a patch gets them into the blood. The label amounts are also tiny [5][36][23][21].
- The FDA-approved needle-free options are GLP-1 pills: Wegovy® (semaglutide) tablets and Foundayo (orforglipron). Both need a prescription. In the OASIS 4 trial, Wegovy® tablets led to 13.6% average weight loss over 64 weeks [32][25].
Status • GLP-1 patches are not FDA-approved. No patch that delivers a GLP-1 medicine is approved in the US [32]. • The patches are sold as dietary supplements. Supplements don't need FDA review or approval before sale [26]. • Patch labels list plant extracts, vitamins and amino acids. They list no semaglutide, tirzepatide or other GLP-1 drug [35]. • A 2026 editorial in the Annals of Pharmacotherapy concluded that these patches break supplement law. That law says supplements must be swallowed [35]. • On March 31, 2026, the FDA sent a warning letter about one seller's "SMGT-GLT-1 Nano Microneedle Patch." The patch was sold for weight loss and type 2 diabetes, and the FDA called it an unapproved new drug [34]. • We searched FDA.gov and FTC.gov on September 29, 2026. We found no FDA action against the brands reviewed here and no FTC action aimed at a GLP-1 patch. • None of 24 products in the 2026 editorial posted a lab certificate of analysis [35]. So a patch may hold the wrong ingredients, the wrong amounts, contaminants or none of what its label lists. • Status checked: September 29, 2026.
Type "glp1 patch" into a search bar or scroll social media. You'll find skin patches with claims like "balances GLP-1 naturally" and "triggers your body's own GLP-1 release." Sold without a prescription, they can look like an easy, needle-free Wegovy®.
No, GLP-1 patches have not been shown to cause weight loss.
Read on to learn what's in these patches and why skin can't absorb semaglutide. We also cover the risks and the needle-free GLP-1 pills the FDA has approved.
What is a GLP-1 patch?
A GLP-1 patch is an adhesive skin patch sold as a dietary supplement. It has "GLP-1" in its name or claims but no GLP-1 medicine inside [35].
The labels list plant extracts, vitamins or amino acids, with 7 ingredients on average [35]. Pharmacy researchers at the University of Connecticut found this. Their 2026 editorial in the Annals of Pharmacotherapy reviewed 24 products [35].
GLP-1 patches take their name from GLP-1 (glucagon-like peptide-1), a gut hormone [16]. The hormone helps release insulin, slows digestion and curbs appetite [16].
GLP-1 patches are sold for weight loss. Brands claim the patches help your body make or balance its own GLP-1. Ledisa claims berberine "triggers your body's own GLP-1 release," but PubMed lists no human trial showing this [23].
A GLP-1 patch is not the same as Ozempic® (semaglutide) or Wegovy®, because it has no semaglutide [35]. Ozempic® is FDA-approved for type 2 diabetes, not weight loss [24].
Ozempic® and Wegovy® are prescription GLP-1 receptor agonists, medicines built to act like GLP-1. They resist DPP-4, the enzyme that breaks natural GLP-1 down within minutes [16][25].
Do GLP-1 patches work for weight loss?
No, there's no evidence that GLP-1 patches cause weight loss. As of September 29, 2026, PubMed and ClinicalTrials.gov list no human trial of these patches [22][23].
The only published paper on supplement patches sold under GLP-1 names is a 2026 editorial [23][35]. It reviewed product listings and was not a trial.
ClinicalTrials.gov returns 59 studies for the search "GLP-1 patch" [22]. The hits study GLP-1 drugs or unrelated treatments. None tests a supplement patch [22].
Customer reviews saying a GLP-1 patch worked can't rule out other causes. A reviewer may have changed diet or exercise at the same time. Only a placebo-controlled trial could tell them apart, and none exists [23].
Is there any weight loss patch that really works?
No weight loss patch has been shown to cause meaningful weight loss in people [23]. The FTC's Gut Check guide calls one claim never true. That claim is "causes substantial weight loss by wearing a product on the body" [9].
A 2024 trial tested an alpha-lipoic acid skin patch in 116 adults with overweight [28]. It appeared in Contemporary Clinical Trials Communications. In the randomized trial, people wore a real or placebo patch 6 hours a day for 2 weeks [28].
Body weight and BMI (body mass index) did not change significantly [28]. Fat thickness under the patch did fall [28].
Why can't a GLP-1 patch deliver semaglutide through the skin?
A GLP-1 patch can't deliver semaglutide or tirzepatide because both drugs are too large to pass through skin. Under the 500 Dalton rule, a molecule generally must weigh under 500 daltons to be absorbed [2]. The rule comes from a 2000 paper in Experimental Dermatology [2].
Semaglutide weighs 4,113.58 daltons and tirzepatide 4,813.53, according to their FDA labels [25][8]. The skin's outer layer, the stratum corneum, is the main barrier. Larger molecules cannot pass it [2].
| Molecule | Where it's used | Molecular weight | Compared with the 500-dalton limit | Shown to reach the blood from a skin patch? |
|---|---|---|---|---|
| Semaglutide | Wegovy®, Ozempic® (shots and pills) | 4,113.58 daltons | About 8 times over | No |
| Tirzepatide | Zepbound®, Mounjaro® (shots) | 4,813.53 daltons | About 10 times over | No |
| Berberine | A top GLP-1 patch ingredient | 336.4 daltons | Under the limit | No human study found |
| Nicotine | Nicotine patches | 162.23 daltons | Under the limit | Yes, in drug patches |
| Estradiol | Menopause hormone patches | 272.4 daltons | Under the limit | Yes, in drug patches |
| Ethinyl estradiol | Birth control patches | 296.4 daltons | Under the limit | Yes, in drug patches |
Semaglutide and tirzepatide weights from their FDA labels; the other weights from PubChem. The 500-dalton limit is from Bos and Meinardi, 2000.
GLP-1 medicines are given as shots because a shot gets past the stratum corneum, the skin's outer barrier. The FDA labels say about 89% of injected semaglutide reaches the blood [25]. For injected tirzepatide, it's 80% [8].
The Wegovy® pill gets semaglutide in through the stomach [25]. It uses an absorption enhancer called SNAC (salcaprozate sodium) [25]. Even with SNAC, only about 1% to 2% of each dose is absorbed [25].
Nicotine, estradiol and birth control patches work because their drugs are small enough to cross skin [20]. Birth control patches pair ethinyl estradiol with norelgestromin (327.5 daltons) or levonorgestrel (312.4 daltons) [20][32]. All of these drugs are used in FDA-approved skin patches [19][32].
Berberine, one of the most common patch ingredients, is small enough to cross skin [20][35]. So size alone doesn't rule it out. But no human study has measured berberine or any other patch ingredient in the blood after patch use [23].
What's in GLP-1 patches, and do any of the ingredients help?
GLP-1 patches most often list berberine, glutamine, cinnamon and pomegranate [35]. None of these has been shown to work from a patch [23].
Pooled trials have tested berberine, cinnamon, chromium and Garcinia cambogia taken by mouth. Each lowered weight by 1.1 kg (2.4 pounds) or less, compared with placebo or control groups [5][36][29][27].
As of September 29, 2026, no study shows that GLP-1 patch ingredients get through skin into the blood in people [23]. Results from pills and powders don't carry over to a patch.
Patch products list tiny amounts of each ingredient. The Kind Patches label lists 8.75 mg of berberine per patch. That is under 1% of the 1 gram a day that NCCIH ties to trial effects [21].
| Ingredient | On these labels | What the labels claim | Best evidence when swallowed (people) | Evidence from a skin patch | Verdict |
|---|---|---|---|---|---|
| Berberine | Kind (8.75 mg), Ledisa, Gentle | Ledisa: "triggers your body's own GLP-1 release" | 23 trials: 0.88 kg more loss than control groups [5]. GLP-1 rise seen only in animal and lab cell studies [37] | None found [23] | Small effect by mouth; unproven in a patch |
| Cinnamon | Kind (2.75 mg), Ledisa, Gentle | Part of "clinically studied ingredients" claims | 21 trials, 1,480 people: 0.92 kg, with widely varying results [36] | None found [23] | Small effect by mouth; unproven in a patch |
| Chromium | Kind (35 mcg), Ledisa | Kind cites one chromium study | 6 trials, 392 people, 12 to 16 weeks: 1.1 kg, low-quality evidence [29] | None found [23] | Small, low-quality evidence |
| Garcinia cambogia | Ledisa | Part of "clinically-studied ingredients" claim | 9 trials: 0.88 kg; clinical relevance uncertain [27] | None found [23] | Uncertain benefit |
| Green tea extract | Gentle (featured), Ledisa (promotional page) | Gentle: "balances GLP-1 naturally" | 6 trials outside Japan, 532 people: 0.04 kg, not significant [18] | None found [23] | No meaningful effect |
| L-glutamine | Kind (3.5 mg), Ledisa | Kind cites one glutamine study | 30 g by mouth raised GLP-1 in 24 adults [14] | None found [23] | Patch amount is far smaller |
| Pomegranate | Kind (1.75 mg), Ledisa | Listed, no specific claim | 13 trials, 513 people: 0.23 kg, not significant [13] | None found [23] | No effect |
Weight figures are average extra loss compared with placebo or control groups. Swallowed evidence is from pooled trials of the ingredient taken by mouth, which is not evidence for a patch. Skin-patch evidence in people: PubMed and ClinicalTrials.gov searches, September 29, 2026. Label amounts: each brand's package label, checked September 29, 2026.
There's no evidence that berberine works like Ozempic®. A 2026 meta-analysis in the International Journal of Obesity pooled 23 randomized trials of berberine taken by mouth [5]. People lost only 0.88 kg (1.9 pounds) more than control groups [5].
Glutamine has raised GLP-1 in people, but only as a 30 g dose taken by mouth [14]. That was a 2009 study of 24 adults in the American Journal of Clinical Nutrition. The dose is more than 8,000 times the 3.5 mg on the Kind label.
Berberine has raised GLP-1 only in animal and lab cell studies [37]. PubMed lists no human trial that measured it [23].
Some weight loss patches contain stimulants. An FDA warning letter in March 2026 described one patch with "caffeine, green tea extract, or other thermogenic compounds" [34]. No study has tested caffeine, guarana, bitter orange or green coffee through the skin in people [23].
NIH's Office of Dietary Supplements calls the evidence that bitter orange helps weight loss "contradictory and weak" [26].
A berberine patch has not been shown to work better than a berberine pill [23]. Berberine pills have trial data, but no study has measured berberine in the blood after patch use [5][23].
Neither a berberine patch nor a berberine pill has been shown to be "nature's Ozempic®." No human trial has compared berberine with any GLP-1 drug [23]. For berberine pills and other supplements sold as GLP-1 boosters, see whether GLP-1 supplements work like the medications.
What do popular GLP-1 patch brands list on their labels?
No study shows that any GLP-1 patch brand works, including Kind Patches, Ledisa and Gentle Patches [23]. We read their labels on September 29, 2026. The labels list only supplement ingredients, and none cites a study of its own patch.
Ledisa's package label, checked September 29, 2026, lists 16 ingredients, including berberine, psyllium extract, alpha-lipoic acid, cinnamon, Garcinia cambogia and chromium picolinate, but no amounts. The label also says the product "does not contain GLP-1 and is not a GLP-1 agonist drug."
| Brand and product name on the label | Ingredients listed | Amounts listed? | GLP-1 wording | Study of the patch itself? |
|---|---|---|---|---|
| Kind Patches, "Berberine Patches (GLP-1 Friendly)" | Berberine 8.75 mg, vitamin B complex 8.25 mg, L-glutamine 3.5 mg, cinnamon 2.75 mg, pomegranate 1.75 mg, chromium 35 mcg | Yes | "GLP-1 Friendly"; 3-pack web address says "formerly GLP-1" | No; cites ingredient studies |
| Ledisa, "GLP-1 Patches" | 16, including berberine, psyllium extract, alpha-lipoic acid, apple cider vinegar extract, resveratrol, cinnamon, Garcinia cambogia, L-glutamine, hops, chromium picolinate, magnesium citrate, pomegranate, vitamins B2, B6 and folic acid, trimethylglycine | No | "Does not contain GLP-1 and is not a GLP-1 agonist drug" | No; claims "clinically-studied ingredients" |
| Gentle Patches, "Weight Loss GLP-1 Patches" | Featured: berberine, green tea, cinnamon; full list not found on the product page | No | "Balances GLP-1 naturally" | No; claims "clinically studied ingredients" |
Package labels as shown on each brand's own product page, checked September 29, 2026. Labels for other brands sold under GLP-1 names could not be verified and are not shown. We don't link to sellers or rank products.
No GLP-1 patch is best for weight loss, because none has human evidence [23].
GLP-1 patch reviews are mixed because no trial shows the patches work. A customer also can't separate a patch from diet or exercise changes [23].
A 2026 editorial in the Annals of Pharmacotherapy found several patch products with 1- to 2-star ratings [35]. Comments on them suggested no effect or side effects. The same editorial found that many of the patches used deceptive advertising [35].
Related reading • Every FDA-approved weight-loss medicine: The approved options side by side, and who each one is for. • The Wegovy® pill: The FDA-approved needle-free semaglutide and what its trial showed. • What GLP-1 is: The hormone behind the name, and how the medicines copy it.
Are GLP-1 patches safe?
GLP-1 patches have not been tested for safety in people [23]. The known risks are skin rash and berberine interactions with some medicines [1][4]. The FDA does not review or approve supplements before they're sold [26].
Known side effects of GLP-1 patches and their ingredients:
- Skin rash: Redness, itching or irritation can appear where the patch sits [1]. Allergic skin reactions are less common [1].
- Medicine interactions: Berberine can add to the blood-sugar lowering of diabetes drugs [4]. It also interacts with cyclosporine [21].
- Slower drug clearance: In healthy men, berberine taken by mouth slowed CYP3A4, a liver enzyme that clears drugs such as midazolam [15].
- Heart problems with bitter orange: NIH lists chest pain, fast heart rate, stroke and heart attack among problems reported with bitter orange [26].
As of September 29, 2026, a search of FDA.gov found no warning letter naming Kind Patches, Ledisa or Gentle Patches. It also found no import alert or consumer update naming them. On March 31, 2026, the FDA did warn one seller that its "SMGT-GLT-1 Nano Microneedle Patch" is an unapproved new drug [34].
A GLP-1 patch can cause a skin rash, as any adhesive patch can. A 2009 review in Advances in Therapy looked at drug patches [1]. It found redness or itching in 20% to 50% of users [1].
Most cases were irritant contact dermatitis, which means irritation where the patch sits [1]. Allergic reactions were less common [1].
CAERS is the FDA's database of adverse event reports for foods and supplements. As of its July 7, 2026 update, no reports named Kind Patches, Ledisa or Gentle Patches [33].
At least 15 CAERS reports named other "GLP-1" products, mostly pills, drinks and probiotics [33]. Ten of them listed a hospital stay. Reports like these don't prove cause [33].
If a supplement patch causes a serious reaction, the FDA asks you to stop using it. You can report the problem through the FDA's Safety Reporting Portal [30].
Berberine, one of the most common patch ingredients, can interact with medicines if enough reaches the blood. NCCIH says it interacts with cyclosporine [21]. A 2026 review in Pharmaceuticals says it can add to the blood-sugar lowering of diabetes drugs [4].
In a study of healthy men, 2 weeks of berberine by mouth raised blood levels of the drug midazolam by about 40% [15]. Midazolam is cleared by the liver enzyme CYP3A4. The authors said drug interactions should be considered when people take berberine [15].
Five groups of people have clear reasons not to use a GLP-1 patch:
- Pregnant or breastfeeding: NCCIH says berberine may be unsafe in pregnancy or breastfeeding and is likely unsafe for infants [21]. Ledisa's label also says not to use it if pregnant or nursing.
- Taking diabetes medicines: Berberine may add to the blood-sugar lowering of these drugs [4]. GLP-1 drug labels already warn that insulin or a sulfonylurea raises the risk of low blood sugar [25].
- Taking cyclosporine or other prescription medicines: NCCIH names a cyclosporine interaction [21]. Berberine also slowed the liver enzyme CYP3A4 in a human study [15]. Ledisa's label says not to use the patch with medication without asking a healthcare professional.
- Already on a GLP-1 medicine: A patch adds no GLP-1 drug. A berberine product may add to the medicine's blood-sugar effect [4].
- Sensitive skin or past patch reactions: Irritation is the most common problem with skin patches [1]. Allergic reactions are less common but can occur [1].
What do GLP-1 patch packages say about wearing them?
GLP-1 patch packages give wear times of up to 8 hours (Kind Patches, Ledisa) or 8 to 12 hours (Gentle Patches). No study links wear time to weight [23]. The table below reports what the labels say and what's known about skin reactions.
| Label direction | Labels that say it | What's known about skin safety |
|---|---|---|
| Apply to clean skin | Kind and Ledisa: clean, hair-free skin; Gentle: clean, dry skin | Most patch reactions are mild irritation where the patch sits [1] |
| Use a new spot each time | Ledisa, Gentle | Rotating sites lowers irritation with drug patches [1] |
| Try a small area first | Gentle | Allergic reactions to patches are uncommon but possible [1] |
| Stop if irritation or an allergic reaction occurs | Ledisa | In 6-month drug-patch trials, 1.7% to 6.8% of users stopped because of skin reactions [1] |
Directions as printed on each brand's package label, checked September 29, 2026. Reported for accuracy, not as instructions.
GLP-1 patch labels from Kind Patches, Ledisa and Gentle Patches don't name a body spot. They ask only for clean skin that is hair-free or dry. No study shows that any spot works better [23].
None of the three GLP-1 patch labels we read mentions wearing a patch at night or in the shower. No study has tested either, so there's no evidence-based answer [23].
Wearing a GLP-1 patch longer than the package says adds no proven benefit [23].
How can you tell if a GLP-1 patch is a scam?
A GLP-1 patch that promises weight loss just from wearing it makes a claim the FTC calls never true [9].
GLP-1 patches are real products, but they are not GLP-1 medicines. Under FTC guidance, health claims generally need randomized, controlled human trials [10]. No such trial of these patches exists [23].
Influencer posts about GLP-1 patches are marketing, not evidence of weight loss. The FTC's Endorsement Guides say influencers must clearly disclose payments or free products from a brand [11].
In December 2025, the FTC issued a final order against NextMed, a telehealth seller [12]. It was not a patch case. The order covered fake testimonials and distorted reviews in GLP-1 ads [12].
Seven red flags show that a GLP-1 patch is being sold with misleading claims:
- "GLP-1" on a product with no GLP-1 drug: None of the labels we read lists semaglutide, tirzepatide or another GLP-1 medicine.
- "Clinically studied ingredients": A study of an ingredient taken by mouth is not a study of the patch. None of the three brands we checked cites a patch study.
- Claims that ingredients soak into your blood: Gentle's page says its compounds are "smaller than the molecules of your skin." No study has measured any patch ingredient in the blood after patch use [23].
- "No side effects": Kind's product page says this. But redness or itching is common with drug patches [1].
- No lab test posted: None of the 24 products in the 2026 editorial posted a certificate of analysis [35]. That is a lab report showing what's inside.
- No supplement disclaimer: Many products in the same editorial lacked the FDA-required supplement disclaimer [35].
- Glowing testimonials: Testimonials are not trial results. The NextMed case shows that GLP-1 ads have used fake ones [12].
Whether you can get money back from a GLP-1 patch subscription depends on each seller's terms. We don't review those terms.
The FTC's NextMed order also covered refunds [12]. NextMed sold GLP-1 programs, not patches. The FTC said NextMed failed to handle cancellation and refund requests on time, and the order requires prompt refunds [12].
How do GLP-1 patches compare with Wegovy®, Zepbound® and Foundayo?
No, GLP-1 patches have not been shown to work as well as GLP-1 shots or pills, because the patches have no trial results. In trials, Wegovy® (semaglutide), Zepbound® (tirzepatide) and Foundayo (orforglipron) led to 7.4% to 20.9% average weight loss [25][8][6].
| Option | Form | Active drug | FDA status | Prescription? | Main trial result | FDA-approved for |
|---|---|---|---|---|---|---|
| GLP-1 patch | Adhesive skin patch | None; plant extracts, vitamins, amino acids | Not approved; sold as a supplement with no FDA review before sale | No | No human trial | Nothing |
| Wegovy® injection | Shot under the skin, weekly | Semaglutide | Approved | Yes | STEP 1: 1,961 adults, 68 weeks, 14.9% average loss vs 2.4% on placebo | Weight loss and maintenance in adults and children 12 and older with obesity, or adults with overweight and a weight-related condition; lowering heart risk in adults with heart disease; MASH liver disease with fibrosis (accelerated approval) |
| Wegovy® pill | Tablet | Semaglutide with SNAC | Approved December 22, 2025 | Yes | OASIS 4: 307 adults, 64 weeks, 13.6% vs 2.4% on placebo | Weight loss and maintenance, and lowering heart risk, in adults only |
| Zepbound® | Shot under the skin | Tirzepatide | Approved | Yes | SURMOUNT-1: 2,539 adults, 72 weeks, 15.0% to 20.9% by dose vs 3.1% on placebo | Weight management in adults with obesity, or overweight and a weight-related condition; moderate to severe obstructive sleep apnea in adults with obesity |
| Foundayo | Tablet | Orforglipron | Approved April 1, 2026 | Yes | ATTAIN-1: 3,127 adults without diabetes, 72 weeks, 7.4% to 11.1% by dose vs 2.1% on placebo | Weight loss and long-term maintenance in adults with obesity, or overweight and a weight-related condition |
FDA labels: Wegovy® (revised 06/2026), Zepbound® (revised 08/2026), Foundayo (revised 07/2026); approval dates from Drugs@FDA. Results are average weight change at the end of each trial. The prescriber sets the dose per the FDA label.
The Wegovy® pill is a needle-free GLP-1 medicine the FDA approved on December 22, 2025 [32]. In the OASIS 4 trial, 307 adults took it for 64 weeks [25]. They lost 13.6% of body weight on average, and people on placebo lost 2.4% [25].
Foundayo (orforglipron) is a second needle-free option, a small-molecule GLP-1 pill approved April 1, 2026 [32][6]. The ATTAIN-1 trial followed 3,127 adults without diabetes for 72 weeks [6]. They lost 7.4% to 11.1% on average, depending on dose, and people on placebo lost 2.1% [6].
In the STEP 1 trial, 1,961 adults took Wegovy® injections for 68 weeks [25]. They lost 14.9% on average, and people on placebo lost 2.4% [25].
Zepbound® (tirzepatide) had the largest average weight loss here: 15.0% to 20.9% over 72 weeks, by dose [8]. That was in SURMOUNT-1, which enrolled 2,539 adults. People on placebo lost 3.1% [8].
Real GLP-1 medicines are prescription-only [32]. Their labels carry serious warnings that a prescriber weighs against your health history [25][8][6].
The Wegovy® and Zepbound® labels carry a boxed warning about thyroid C-cell tumors [25][8]. Semaglutide and tirzepatide caused these tumors in rodents. It is unknown whether they do in people [25][8].
As of September 29, 2026, no GLP-1 medicine is sold over the counter in the US [32]. Wegovy®, Zepbound®, Saxenda® (liraglutide), Ozempic®, Mounjaro® (tirzepatide), Rybelsus® (semaglutide) and Foundayo all need a prescription [32].
Eating a meal makes the gut release the hormone GLP-1 [16]. But the body breaks it down within minutes [16]. For foods and supplements sold as natural GLP-1 boosters, see our guide to GLP-1 supplements.
Is a real GLP-1 patch coming?
A real GLP-1 patch is not available yet. As of September 29, 2026, two microneedle array patches that deliver semaglutide are in Phase 1 trials [22]. Neither has results [22].
A microneedle array patch uses tiny needles to deliver a drug into the skin [22]. GLP-1 patches sold online contain no drug [35]. No microneedle or skin-patch GLP-1 drug is FDA-approved; every approved GLP-1 medicine is a shot or a tablet [32].
| Research patch | Sponsor | Trial ID | Phase | Started | Planned size | Status |
|---|---|---|---|---|---|---|
| DWRX5003 | Daewoong Pharmaceutical | NCT07539415 | 1 | May 6, 2026 | About 72 healthy adults | Recruiting |
| VX-201 | Terrestrial Bio | NCT07673900 | 1 | June 15, 2026 | About 62 adults with overweight or obesity | Recruiting |
ClinicalTrials.gov records, checked September 29, 2026 [22].
No one can predict when a GLP-1 patch could be approved. Both semaglutide patches are in Phase 1 trials, which mainly test safety [22]. The trials list estimated primary completion dates of October 27, 2026 and February 10, 2027 [22].
Other published research on skin delivery of GLP-1 drugs is still in animals or the lab [23]. One example is a study of semaglutide microneedles in diabetic rats. PubMed lists no published clinical trial of a GLP-1 drug given through the skin [23].
Are GLP-1 patches worth the money?
GLP-1 patches aren't worth the money for weight loss, because no evidence shows they work [23].
A GLP-1 patch is not a cheaper version of Ozempic® or Wegovy®. It contains no semaglutide or any other GLP-1 drug [35].
An HSA or FSA probably won't cover a GLP-1 patch. IRS Publication 502 defines which medical expenses count [17]. It counts supplements only if a medical practitioner recommends them for a specific condition a physician has diagnosed [17].
Insurance may cover a real GLP-1 medicine, though coverage varies by plan. A June 10, 2026 CMS memo says Medicare Part D excludes drugs used for weight loss [3]. The Medicare GLP-1 Bridge runs outside Part D [3].
The Bridge is a CMS demonstration that covers certain GLP-1 drugs for weight management [3]. It runs from July 1, 2026 to December 31, 2027, for eligible enrollees [3]. See what GLP-1 medicines cost and how coverage works.
Who qualifies for a real GLP-1 medicine instead of a GLP-1 patch?
Adults with obesity may qualify for Wegovy®, Zepbound® or Foundayo instead of a GLP-1 patch [25][8][6]. So may adults with overweight and at least one weight-related health problem [25][8][6].
The main trials of Wegovy®, Zepbound® and Foundayo enrolled adults with a BMI of 30 or higher [25][8][6]. Adults with a BMI of 27 or higher and a weight-related health problem could also join. The labels' approved uses don't list a BMI number.
- Teens 12 and older with obesity: Wegovy® injections are approved for them [25]. Wegovy® tablets and Zepbound® are for adults only [25][8].
- Adults with obesity and sleep apnea: Zepbound® is also approved for moderate to severe obstructive sleep apnea in these adults [8].
- Not with another GLP-1 medicine: The labels advise against taking Wegovy®, Zepbound® or Foundayo with another GLP-1 receptor agonist [25][8][6].
People with a personal or family history of medullary thyroid carcinoma (MTC), a type of thyroid cancer, should not take Wegovy®, Zepbound® or Foundayo [25][8][6]. The same goes for people with multiple endocrine neoplasia syndrome type 2 (MEN 2), an endocrine system condition. All three FDA labels list this in a boxed warning about thyroid C-cell tumors [25][8][6].
The first step toward a real GLP-1 medicine is a visit with a primary care provider or an obesity medicine specialist. A licensed telehealth service is another option. See how to get a GLP-1 prescription online.
The prescriber sets the dose per the FDA label.
When should you see a healthcare provider?
See a healthcare provider if a GLP-1 patch leaves a rash that spreads, blisters or doesn't clear after removal.
Talk with your prescriber before using any berberine product if you take diabetes medicines, cyclosporine or a GLP-1 medicine [4][21]. Berberine may add to blood-sugar lowering or change how some drugs work [15].
Call 911 or go to the nearest ER for signs of a severe allergic reaction, such as trouble breathing or a swollen face, lips, tongue or throat. Do the same for chest pain, signs of a stroke, or very low blood sugar with confusion or slurred speech [25].
Bottom line
- GLP-1 patches hold no GLP-1 medicine. As of September 29, 2026, PubMed and ClinicalTrials.gov list no human trial showing they cause weight loss.
- Semaglutide and tirzepatide are far too large to pass through skin. Patch ingredients show small or no effects even when swallowed.
- The main known risks are skin irritation and berberine interactions with some medicines. You also can't be sure what a patch really contains.
- The FDA-approved needle-free choice is a GLP-1 pill, such as the Wegovy® pill or Foundayo, with a prescription. Start with our guide to GLP-1 for weight loss.
Frequently asked questions
How quickly do GLP-1 patches work?
No one can say how quickly GLP-1 patches work, because no human study has measured any effect. As of September 29, 2026, PubMed and ClinicalTrials.gov list no trial of these patches [22][23]. Timelines on product pages are marketing, not results. For comparison, the Wegovy® and Zepbound® label trials tracked weight for 68 and 72 weeks [25][8].
Do the Kind GLP-1 patches really work?
No study shows that Kind Patches' GLP-1 product works. The label lists 8.75 mg of berberine per patch. NCCIH says berberine's weight effects showed up mainly above 1 gram a day, taken by mouth for more than 8 weeks [21]. The brand's cited studies test single ingredients, not the patch. It now sells the patch as "Berberine Patches (GLP-1 Friendly)."
Can you wear a GLP-1 patch with Ozempic® or Mounjaro®?
No study has tested wearing a GLP-1 patch with Ozempic® (semaglutide) or Mounjaro® (tirzepatide), so ask your prescriber first [23]. The patch adds no GLP-1 drug. Berberine, a common patch ingredient, may add to the blood-sugar lowering of diabetes medicines [4]. Ozempic® and Mounjaro® are FDA-approved for type 2 diabetes, not weight loss [24][7].
Are GLP-1 patches legal?
The legal status of GLP-1 patches as supplements is disputed. Federal law defines a dietary supplement as a product "intended for ingestion" [31]. In 2019, the FDA used that rule to say a CBD skin patch was not a supplement [31]. A 2026 Annals of Pharmacotherapy editorial concluded that these patches are illegal [35]. In March 2026, the FDA called one seller's weight-loss microneedle patch an unapproved new drug [34].
Are GLP-1 patches FDA-approved?
As of September 29, 2026, no GLP-1 patch is FDA-approved [32]. None that delivers a GLP-1 medicine is sold in the US. The patches sold online are supplements, which the FDA doesn't review or approve before sale [26]. Two microneedle patches that deliver semaglutide began Phase 1 trials in 2026, with no results yet [22].
Sources
- 1. Ale, I., Lachapelle, J. M., & Maibach, H. I. (2009). Skin tolerability associated with transdermal drug delivery systems: An overview. Advances in Therapy, 26(10), 920-935. https://doi.org/10.1007/s12325-009-0075-9
- 2. Bos, J. D., & Meinardi, M. M. (2000). The 500 Dalton rule for the skin penetration of chemical compounds and drugs. Experimental Dermatology, 9(3), 165-169. https://doi.org/10.1034/j.1600-0625.2000.009003165.x
- 3. Centers for Medicare & Medicaid Services. (2026, June 10). Medicare GLP-1 Bridge expectations and frequently asked questions [Memorandum]. https://www.cms.gov/files/document/medicare-glp-1-bridge-expectations-faqs.pdf
- 4. Dumitru, C. N., Marcu, T., Dumitru, A. O., Tudor, S. S., Ferțu, I. D., Elisei, A. M., & Goroftei, L. (2026). Berberine-drug interactions: Mechanisms, clinical relevance and risk stratification. A narrative review. Pharmaceuticals, 19(8), 1313. https://doi.org/10.3390/ph19081313
- 5. Elahi Vahed, I., Shahir-Roudi, E., Nojumi, S., Golmohammadi, S., Moradi Shahrebabak, M., Sharafi Tafreshi Moghadam, N., Bagheryan, A. S., Moftakhar, M., Shamsipour, F., Jafari, M., Soltaninejad, H., & Rahmanian, M. (2026). The effect of berberine on obesity indices: A systematic review and meta-analysis. International Journal of Obesity, 50(1), 53-73. https://doi.org/10.1038/s41366-025-01943-x
- 6. Eli Lilly and Company. (2026). FOUNDAYO (orforglipron) tablets, for oral use: Prescribing information (Revised 07/2026). U.S. Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220934s003lbl.pdf
- 7. Eli Lilly and Company. (2026). MOUNJARO (tirzepatide) injection: Prescribing information (Revised 08/2026). U.S. Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215866s044s045lbl.pdf
- 8. Eli Lilly and Company. (2026). ZEPBOUND (tirzepatide) injection: Prescribing information (Revised 08/2026). U.S. Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806Orig1s041correctedlbl.pdf
- 9. Federal Trade Commission. (2014). Gut check: A reference guide for media on spotting false weight loss claims. https://www.ftc.gov/business-guidance/resources/gut-check-reference-guide-media-spotting-false-weight-loss-claims
- 10. Federal Trade Commission. (2022). Health products compliance guidance. https://www.ftc.gov/business-guidance/resources/health-products-compliance-guidance
- 11. Federal Trade Commission. (2023). Guides concerning use of endorsements and testimonials in advertising (16 C.F.R. Part 255; 88 Fed. Reg. 48102). Retrieved September 29, 2026, from https://www.ecfr.gov/current/title-16/chapter-I/subchapter-B/part-255
- 12. Federal Trade Commission. (2025, December 3). FTC approves final order against telehealth provider NextMed over charges it used deceptive advertising claims to sell GLP-1 weight-loss programs [Press release]. https://www.ftc.gov/news-events/news/press-releases/2025/12/ftc-approves-final-order-against-telehealth-provider-nextmed-over-charges-it-used-deceptive
- 13. Gheflati, A., Mohammadi, M., Ramezani-Jolfaie, N., Heidari, Z., Salehi-Abargouei, A., & Nadjarzadeh, A. (2019). Does pomegranate consumption affect weight and body composition? A systematic review and meta-analysis of randomized controlled clinical trials. Phytotherapy Research, 33(5), 1277-1288. https://doi.org/10.1002/ptr.6322
- 14. Greenfield, J. R., Farooqi, I. S., Keogh, J. M., Henning, E., Habib, A. M., Blackwood, A., Reimann, F., Holst, J. J., & Gribble, F. M. (2009). Oral glutamine increases circulating glucagon-like peptide 1, glucagon, and insulin concentrations in lean, obese, and type 2 diabetic subjects. American Journal of Clinical Nutrition, 89(1), 106-113. https://doi.org/10.3945/ajcn.2008.26362
- 15. Guo, Y., Chen, Y., Tan, Z. R., Klaassen, C. D., & Zhou, H. H. (2012). Repeated administration of berberine inhibits cytochromes P450 in humans. European Journal of Clinical Pharmacology, 68(2), 213-217. https://doi.org/10.1007/s00228-011-1108-2
- 16. Holst, J. J. (2007). The physiology of glucagon-like peptide 1. Physiological Reviews, 87(4), 1409-1439. https://doi.org/10.1152/physrev.00034.2006
- 17. Internal Revenue Service. (2026). Publication 502 (2025), Medical and dental expenses. https://www.irs.gov/publications/p502
- 18. Jurgens, T. M., Whelan, A. M., Killian, L., Doucette, S., Kirk, S., & Foy, E. (2012). Green tea for weight loss and weight maintenance in overweight or obese adults. Cochrane Database of Systematic Reviews, 12, CD008650. https://doi.org/10.1002/14651858.CD008650.pub2
- 19. Murphy, M., & Carmichael, A. J. (2000). Transdermal drug delivery systems and skin sensitivity reactions: Incidence and management. American Journal of Clinical Dermatology, 1(6), 361-368. https://doi.org/10.2165/00128071-200001060-00004
- 20. National Center for Biotechnology Information. (2026). PubChem compound summaries: Berberine, nicotine, estradiol, ethinyl estradiol, norelgestromin and levonorgestrel. Retrieved September 29, 2026, from https://pubchem.ncbi.nlm.nih.gov/
- 21. National Center for Complementary and Integrative Health. (2023). Berberine and weight loss: What you need to know. https://www.nccih.nih.gov/health/berberine-and-weight-loss-what-you-need-to-know
- 22. National Library of Medicine. (2026). ClinicalTrials.gov [Database; records NCT07539415 and NCT07673900; searches for GLP-1 and weight loss patch studies]. Retrieved September 29, 2026, from https://clinicaltrials.gov/
- 23. National Library of Medicine. (2026). PubMed [Database; searches for GLP-1 patch, weight loss patch, berberine and transdermal GLP-1 studies]. Retrieved September 29, 2026, from https://pubmed.ncbi.nlm.nih.gov/
- 24. Novo Nordisk. (2026). OZEMPIC (semaglutide) injection: Prescribing information (Revised 05/2026). U.S. Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/209637s038lbl.pdf
- 25. Novo Nordisk. (2026). WEGOVY (semaglutide) injection and WEGOVY (semaglutide) tablets: Prescribing information (Revised 06/2026). U.S. Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/218316s007lbl.pdf
- 26. Office of Dietary Supplements, National Institutes of Health. (n.d.). Dietary supplements for weight loss: Fact sheet for health professionals. Retrieved September 29, 2026, from https://ods.od.nih.gov/factsheets/WeightLoss-HealthProfessional/
- 27. Onakpoya, I., Hung, S. K., Perry, R., Wider, B., & Ernst, E. (2011). The use of Garcinia extract (hydroxycitric acid) as a weight loss supplement: A systematic review and meta-analysis of randomised clinical trials. Journal of Obesity, 2011, 509038. https://doi.org/10.1155/2011/509038
- 28. Sooklert, K., Thamakaison, S., Nilyai, S., Cherdchom, S., Rojanathanes, R., & Sereemaspun, A. (2024). The effects of alpha-lipoic acid transdermal patch for local subcutaneous fat reduction: A randomized, placebo-controlled, clinical trial in overweight volunteers. Contemporary Clinical Trials Communications, 42, 101402. https://doi.org/10.1016/j.conctc.2024.101402
- 29. Tian, H., Guo, X., Wang, X., He, Z., Sun, R., Ge, S., & Zhang, Z. (2013). Chromium picolinate supplementation for overweight or obese adults. Cochrane Database of Systematic Reviews, 11, CD010063. https://doi.org/10.1002/14651858.CD010063.pub2
- 30. U.S. Food and Drug Administration. (n.d.). How to report a problem with dietary supplements. Retrieved September 29, 2026, from https://www.fda.gov/food/dietary-supplements/how-report-problem-dietary-supplements
- 31. U.S. Food and Drug Administration. (2019, July 22). Warning letter: Curaleaf, Inc. (MARCS-CMS 579289). https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/curaleaf-inc-579289-07222019
- 32. U.S. Food and Drug Administration. (2026). Drugs@FDA: FDA-approved drugs [Database]. Retrieved September 29, 2026, from https://www.accessdata.fda.gov/scripts/cder/daf/
- 33. U.S. Food and Drug Administration. (2026). openFDA food adverse event reports (CAERS) [Database; data updated July 7, 2026]. Retrieved September 29, 2026, from https://open.fda.gov/apis/food/event/
- 34. U.S. Food and Drug Administration. (2026, March 31). Warning letter: FormPour (MARCS-CMS 722215). https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/formpour-722215-03312026
- 35. White, C. M., Tai, Z., & Nuzi, K. (2026). Transdermal "natural GLP-1" dietary supplements violate law and place patients at risk [Editorial]. Annals of Pharmacotherapy, 60(8), 813-816. https://doi.org/10.1177/10600280251407145
- 36. Yazdanpanah, Z., Azadi-Yazdi, M., Hooshmandi, H., Ramezani-Jolfaie, N., & Salehi-Abargouei, A. (2020). Effects of cinnamon supplementation on body weight and composition in adults: A systematic review and meta-analysis of controlled clinical trials. Phytotherapy Research, 34(3), 448-463. https://doi.org/10.1002/ptr.6539
- 37. Yu, Y., Liu, L., Wang, X., Liu, X., Liu, X., Xie, L., & Wang, G. (2010). Modulation of glucagon-like peptide-1 release by berberine: In vivo and in vitro studies. Biochemical Pharmacology, 79(7), 1000-1006. https://doi.org/10.1016/j.bcp.2009.11.017
Comments